Montreal, March 8, 2016 – Trans-Hit Bio, a CRO developing and promoting discovery and validation biomarker models, has experienced over the past year an accelerated development translating into a two-fold increase in revenues and a number of recruitments within its Montreal-based scientific team.
The NEOMED Institute attracts, creates, and leads a network of small and medium enterprises (SMEs) to take charge of what pharma companies were doing in the discovery of new drugs, and to bridge the gap between academic innovation and industry needs.
Trans-Hit Bio’s management therefore decided to relocate its operations to NEOMED’s site in Laval, a new division dedicated to biologics and vaccines, which was created following a strategic partnership with the GSK group in 2015.
Max Fehlmann, President and CEO of the NEOMED Institute, commented, “I have known the key players at Trans-Hit Bio for years, and I am delighted to welcome them to our Laval site where their knowledge of the contract research world will promote discussions with a high added value for the Institute, in particular with NEOMED-LABS, a CRO specialized in clinical serology and immunomonitoring for the development of new vaccines and biologics.”
Pascal Puchois, Trans-Hit Bio Founder and CEO, added, “Trans-Hit and our whole team are very lucky to be welcomed into a campus where both the talented immunology researchers who made GSK’s reputation in the vaccine field, as well as start-ups with activities that are close and synergistic to THB’s, are working. This move will enable us to accelerate our gold standard infectious diseases biobanks network project and to widen our laboratory services portfolio to expert immunology and immune-oncology segments.”
For more information on Trans-Hit Bio, please send an email to: email@example.com.
For more information on NEOMED, please send an email to: firstname.lastname@example.org.
ABOUT TRANS-HIT BIO (www.trans-hit.com)
THB is the human tissue procurement company with the deepest and widest collection capability for biospecimens and clinical samples for R&D purposes through an unrivaled worldwide partner-network of state-of-the-art biorepositories. We facilitate direct interactions between our customers and academic biobanks allowing the expertise of academics to be leveraged and acknowledged. The company, led by a team of scientists with superior knowledge of biomarker development, advise and provide services to biopharmaceutical and IVD companies in various fields, including oncology, infectiology, CNS diseases, etc. Our aim is to keep growing as the leading CRO targeting biomarker R&D teams with an outstanding reputation and a proven contribution to personalized medicine development.
ABOUT THE NEOMED INSTITUTE (http://neomed.ca/)
The NEOMED Institute is a not-for-profit organization whose mission is to create a bridge between basic research and the commercialization of new drugs by providing industrial expertise in drug discovery and development, combined with funding and a favourable ecosystem, to transform innovations into solid therapeutic solutions. NEOMED drives drug discovery activities up to the stage of human proof of concept.
The NEOMED Institute has two fully integrated research and development facilities: one in Technoparc Montréal’s Saint-Laurent Campus, specializing in small molecule therapeutics, and the other facility, specializing in the development of biologics and vaccines, in Laval. Both facilities function as open-access drug discovery hubs housing independent commercial businesses and providing a dynamic environment that stimulates collaboration, innovation, and creativity.
The NEOMED Institute is jointly funded by the pharmaceutical industry, the Ministère de l’Économie, de l’Innovation et des Exportations du Québec, and the Networks of Centres of Excellence (NCE) of Canada.
New mailing address:
525 Boul. Cartier West
CANADA H7V 3S8